Abstract
INTRODUCTION
The German Aortic Valve Score (GAVS) I was developed to calculate risk-adjusted mortality rates for reasons of quality assurance, which in Germany is obligatory under requirements of the German social code. The score was calculated on the basis of 10 574 cases of surgical aortic valve replacement (SAVR) and 573 cases (5%) with transcatheter aortic valve implantation (TAVI) performed in 2008 [1] . Since then, the score was recalibrated every year using the data set of 2 years before to perform quality assurance for the preceding year. However, a significant annual shift of regression coefficients indicated a significant change in the risk of the procedures. Therefore, the score had to be remodelled. The resulting GAVS II is presented in this article.
MATERIALS AND METHODS
The methods remained the same as described previously [1, 2] . The goal of the study was to develop a logistic regression risk model for the end-point of in-hospital deaths. Data were derived from the mandatory national quality assurance for coronary and aortic valve surgery and for transcatheter aortic valve procedures. These data were transferred electronically from all heart centres in Germany on an annual basis, and completeness was verified for each institution by comparing the transferred data with the number of reimbursed cases per year. We achieved nearly 100% completeness [3, 4] . The collected cases were grouped into 3 main categories: coronary artery bypass surgery (CABG), isolated aortic valve replacement (AVR), both for surgical aortic valve implantation and for TAVI and for combinations of CABG and SAVR. The underlying data set description for the new GAVS II remained the same as it was for the published GAVS I [1] .
Data sets for development and verification of the scoring system were created by randomly assigning the pooled cases from beginning 2011 to the end of 2012 in 2 equal groups: one for the development of the risk model and the other for validation purposes.
The primary selection of risk factors was based on the existing model and on other established risk models for heart diseases [1, 2] . For each of these parameters, prevalence, the related mortality rate and bivariate relative risks together with 95% confidence intervals were calculated.
The selection of parameters for the logistic regression model was performed by backward selection. Every risk factor that did not reach significant influence in the expected direction was manually excluded from the analyses in an iterative procedure.
The Hosmer-Lemeshow test statistics was used for testing the calibration of the model, and the area under the receiver operating characteristic curve was calculated to verify the quality of discrimination. All analyses were performed using SPSS version 19.0.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
In 2011 and 2012, 38 281 cases were submitted. Of these, 36 183 data sets were evaluable, which represents an overall completeness of 94.5%.
The rate of completeness in the SAVR group was 94.5% (19 945 of 21 100 cases). In the TAVI group, the rate of completeness had improved to 94.5% (16 238 of 17 181 cases) when compared with the 90.4% completion rate from the 2007 data set. Of the 36 183 complete data sets, 18 054 data sets were randomized for the study cohort. Patient characteristics are summarized in Table 1 . Table 1 summarizes the prevalence, odds ratios and relative risks of the 28 characteristics that were evaluated. Compared to the GAVS I with 22 parameters, of which some were combined, the following additional items were included in the first step: '1-, 2-or 3-vessel coronary heart disease' according to coronary angiography, American Society of Anesthesiologists risk levels, implanted pacemaker or implantable cardioverter-defibrillator, intravenous inotropes and mechanical circulatory support. The latter 2 items were included in an aggregate parameter ('critical preoperative status') for the GAVS I risk model. 'Mechanical circulatory support prior to operation' had the lowest prevalence (1.93%, n = 35) of any of the 28 risk factors included in the regression model. All risk factors but 'mechanical support' and 'cardiopulmonary reanimation within 48 h' had a prevalence of >2.0% in the study population. The categories 'respirator dependency', 'implanted pacemaker/implantable cardioverter-defibrillator', 'previous percutaneous coronary intervention', 'structural pulmonary disease', 'concomitant neurological disease', 'urgency' and 'inotrope dependency' were excluded after multivariable analysis.
Statistical analysis
Of the risk factors from the 2012 version of the regression model, the items 'emergency procedure', 'chronic obstructive pulmonary disease' and 'previous myocardial infarction' were not found to be significant after the multivariable analysis. The absence of the risk factors 'pulmonary arterial hypertension' and 'cardiac arrhythmia on admission' was incorporated in the new model as protective factors with a negative regression coefficient.
The specific mortality risk of age showed a broadly linear correlation to age, especially in the relevant cohort older than 40 years (Fig. 1) .
The overall in-hospital mortality rate was 4.53% (817 of 18 054, EuroSCORE: 13.5 ± 15.01%). In the subgroup of 'conventional AVR', there were 301 deaths (3.01%, 95% confidence interval:
2.69-3.36%, n = 9997, EuroSCORE: 6.08 ± 8.44%); in the TAVI subgroup, there were 516 deaths (6.40%, 95% confidence interval: 5.89-6.96%, n = 8057, EuroSCORE: 22.83 ± 16.17%).
After modelling with multiple regression algorithms, 18 of the initial 28 risk factors remained with a statistically significant impact on the mortality rate in isolated AVR procedures with P < 0.05 (Table 2) .
Eighteen risk factors have been incorporated in the new model. From the 15 risk factors of the 2012 model, the operators 'emergency surgery', 'myocardial infarction <48 h', 'critical preoperative status', 'moderately depressed left ventricular ejection fraction' and 'concomitant chronic obstructive pulmonary disease' did not show a significant impact on the multivariable analysis and therefore were not incorporated in the new model, whereas the risk factors 'angina at rest or with mild exertion' (Canadian Cardiovascular Society Classes III and IV), 'cardiogenic shock within 48 h', 'cardiopulmonary reanimation <48 h', 'American Society of Anesthesiologists Class IV or V', 'diabetes with insulin regimen or untreated diabetes', 'coronary artery disease' and 'preoperative treatment with mechanical assist device' were included. Table 2 summarizes the definitions of the risk factors as well as the odds ratios and the regression coefficients. Although higher values correlate with increased risk, negative numbers stand for a protective effect of the corresponding factor. The odds ratios represent the increased odds of dying in the hospital if the other factors remain unchanged. If, e.g. peripheral artery disease was present in a patient, the odds for dying in the hospital would be increased by a factor of 1.28. In the 2012 version, the odds would have increased by a factor 1.98.
In the final model, age was treated as a cumulative risk factor: the regression coefficient is multiplied by the age of the patient.
The precise risk, q, can be calculated by taking the sum X of the regression coefficients (Table 2) according to the present risk factors of a specific patient using the following formula:
where q is risk of in-hospital death; X i is manifestation of the risk factor i (e.g. 0 or 1 for dichotomous risk factors, age in years for age as risk factor, 1-4 for coronary heart disease); ß i is regression coefficient for risk factor i and ß 0 is a constant.
The calibration of the model was tested in the control cohort with the Hosmer-Lemeshow method. Predicted and observed mortality rates of the 10 risk groups are listed in Table 3 . The derived P-value of 0.411 shows good calibration.
The area under the receiver operating characteristic curve with a value of 0.741 ( Fig. 2) is satisfactory. In comparison, using the GAVS I with the same data, the Hosmer-Lemeshow test resulted in a P-value of 0.011, which suggests a rejection of the GAVS I model, although the area under the receiver operating characteristic curve for the GAVS I resulted in a C-statistic of 0.738 with this data set.
DISCUSSION
The aim of this work was to read just the GAVS, published in 2012, which is based on the comprehensive national data pool from 2008. The GAVS I was developed to estimate preoperative risk in the context of inter-hospital benchmarking and quality control [1] . 
CATHETER-BASED VALVE OPERATIONS
The score is recalibrated annually with the data from the previous calendar year using the national quality control data set. However, with the widespread adoption of transcatheter valve replacement techniques, clinical practices and the patient cohort receiving valve replacement have changed. In 2012, 48% of the procedures were performed interventionally (n = 9341), which is more than a 10-fold increase compared with 2008, when only 634 cases of AVR were performed via TAVI (5.2% of the patients database for the GAVS I). As a consequence, the odds ratios of some risk factors have changed significantly. For example, the risk factor 'age >85 years' had an odds ratio of 10.5 based on the 2008 data; it dropped to 2.7 with the data from 2011 [3] .
In-hospital results of the German Aortic Valve Registry (GARY) have shown that the GAVS I over-predicts deaths in high-risk patients who have TAVI [5] . Similarly, in the 2012 annual report of the Institute for Quality Control, the GAVS I was shown to underpredict the mortality rate in low-and intermediate-risk patients (<3% and 3-6% predicted mortality rate) while over-predicting the mortality rate in the high-risk subgroup (>10% predicted mortality) [6] . This observation is reflected in the P-value of 0.011 for the Hosmer-Lemeshow test of the GAVS I, calculated on the basis of the control cohort of this study.
The reduced accuracy of scores developed with data from the cohorts of surgical patients has been reported for other Halkin et al. [7] who assessed the predictive accuracy of surgical and interventional scoring systems on a cohort of Israeli patients having transcatheter aortic valve replacement also reported a limited predictive accuracy for surgical scoring systems as well as for the TAVI-specific scoring systems from the FRANCE-2 and OBSERVANT studies.
Because surgical scores have reduced predictive accuracy when applied to patients undergoing TAVI, several scoring systems such as OBSERVANT, FRANCE-2 and SURTAVI have been developed exclusively for patients undergoing TAVI [8] [9] [10] . Although these specialized scores have been shown to be well calibrated, they also have been criticized for their limited predictive capacity, as none exceeded an AUC value of 0.6 in the c-statistic when independently assessed [11, 12] . The reason for this finding may be found in the small number of patients used to calculate these specialized scores or in the variety of TAVI technologies with specific possible complications with a differing sensitivity for single risk factors.
We used the exhaustive data pool of the national benchmarking project. Because all cases are cross-referenced with the hospital data submitted for reimbursement and checked for completeness and statistical aberrations with audits conducted by the National Institute for Benchmarking and Quality Control, the resulting data set offers a virtually complete collection of all AVR procedures performed in Germany for any given calendar year.
To re-evaluate the GAVS, we used the combined data pool of the years 2011 and 2012. In the resulting data set, 44.9% of the cases were treated with aortic valve replacement, which allows for a representative data set for surgical as well as for catheterbased AVR.
As was done in the GAVS I, the in-hospital mortality rate was chosen as the primary predicted outcome. Because in-hospital death is a mandatory item in the data for quality control and for reimbursement, the use of this end-point allows for easy validation of the data.
Although the in-hospital mortality rate is generally a reliable parameter for determining quality of care, a disadvantage of this end-point is that the score can only be used to predict the shortterm risk of a patient [13] . The 1-year data of the GARY show that, although for AVR procedures, the cumulative number of deaths stabilized after the 30-day end-point, the number of deaths of patients having TAVI continues to rise throughout the first year after the procedure [14] .
In our population from 2011 to 2012, the mortality rate of patients having SAVR was 2.9% and that of patients having TAVI was 6.3%. The mortality rate of patients having surgical aortic valve implantation is similar to that reported in the literature and is slightly below the in-house mortality rate of the 2008 study population [1] . The mortality rate of patients having TAVI procedures closely matches the in-hospital mortality rate reported from the GARY, which was 5.1% for endovascular TAVI and 7.7% for transapical TAVI [5] .
The Hosmer-Lemeshow statistics shows that the score is well calibrated. The c-statistic of the GAVS II gives an AUC value of 0.74 (Fig. 2) , whereas the GAVS I performed better in this regard, with an AUC of 0.808. To ensure that our result was accurate, we recalculated the c-statistic for the GAVS I using data from the control group of the actual study. This calculation resulted in a c-statistic of 0.739, which is like that of the GAVS II. Yet, in the Hosmer-Lemeshow test, the predicted value of the GAVS I calculated from the actual control group resulted in a P-value of 0.011, suggesting a rejection of the GAVS I model. The EuroSCORE published in 1999 with data from 1995 provided a c-statistic of 0.759 for its validation group. The decrease in the c-statistic of the GAVS I for its corresponding data from the 2008 data and the c-statistic of the GAVS II (0.808 vs 0.741) may be interpreted as indicating that the impact of common risk factors has decreased over time. This change can be explained mainly by the fact that increased knowledge and experience as well as better techniques led to better results, which is especially true for the group of TAVI patients. Distinct differences in outcomes facilitate good discrimination properties of risk models. In other words, if, in constant patient characteristics, the mortality rate that is related to the risk factors of the model decreases due to improved procedural techniques or overall standard of care, random events gain in importance and the discriminatory ability of the risk model becomes worse. This situation obtains for the TAVI procedures; as high-risk cases are shifted from SAVR to TAVI, the same situation holds true for SAVR.
In addition, differences may exist in the interactions of risk factors associated with SAVR and with TAVI, which would support that argument that 2 independent scores should be developed and that TAVI and SAVR should be benchmarked separately.
The GAVS was developed for interinstitutional benchmarking in the context of mandatory quality assurance for isolated aortic valve procedures in Germany. Therefore, the quality of the entire institution should be judged. This approach includes preoperative evaluation, indication of the setting by the heart team and the treatment itself. Specific benchmarking of either the TAVI procedure or the surgical aortic valve implantation procedure would exclude decision making for one procedure or another.
Furthermore, clinical decision making for the treatment by TAVI or SAVR implies a preselection of risk beyond typical risk factors. A multitude of possible risks, where each occurs too infrequently to be included in a risk model, would not be randomly assigned to 1 of the 2 treatment options. Some of these risks are absolute or relative contraindications for one of the treatment options.
The results of the German quality assessment show better results for endovascular TAVI procedures than for transapical TAVI procedures. Should there be two TAVI scores?
The more specific and uniform a patient cohort and its treatment regimen are, the better is the quality of discrimination of a risk model for this combination. That is why 3 risk scores for cardiac operations (isolated AVR, isolated CABG and CABG + AVR) have been developed for the purposes of quality assessment in Germany instead of a combined score such as the EuroSCORE. In CABG, this issue occurs in a weakened but similar form: offpump versus on-pump surgery and complete arterial versus classic combined venous and arterial grafts. A subtle analysis could give different odds ratios for single risk factors in the subgroups. However, the decision for one treatment or another is already part of the treatment itself. Therefore, in the German quality control system, where institutions, not departments, medical specialties or treatment options, are compared, the decision was made to develop one score for the entire entity of isolated aortic valve implantations.
General purpose surgical scores such as the EuroSCORE I and the EuroSCORE II performed well in the SAVR groups [13, 15] . However, when applied to TAVI cohorts, these surgical scores and the specialized TAVI scores mentioned above have shown AUC values below 0.7. Therefore, we believe that the GAVS II performs with good accuracy in our population, which comprises 45% of TAVI cases [6, 9, 11, 16, 17] .
The GAVS II is based on the German population and the German public health service, where the prevalence of TAVI is high compared to other countries. This difference should be kept in mind when applying the GAVS II. It should fit best for similar groups with comparable decision strategies concerning the indication for one or the other type of aortic valve implantation. To support individual indications in daily practice, it would be helpful to develop 2 additional scores based on the large data pool of the German quality assurance system: one score specifically for TAVI and the other for SAVR.
